These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 22842675)

  • 1. Comparative evaluation of the potency and antigenicity of two distinct BoNT/A-derived formulations.
    Brown M; Nicholson G; Ardila MC; Satorius A; Broide RS; Clarke K; Hunt T; Francis J
    J Neural Transm (Vienna); 2013 Feb; 120(2):291-8. PubMed ID: 22842675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OnabotulinumtoxinA Displays Greater Biological Activity Compared to IncobotulinumtoxinA, Demonstrating Non-Interchangeability in Both In Vitro and In Vivo Assays.
    Rupp D; Nicholson G; Canty D; Wang J; Rhéaume C; Le L; Steward LE; Washburn M; Jacky BP; Broide RS; Philipp-Dormston WG; Brin MF; Brideau-Andersen A
    Toxins (Basel); 2020 Jun; 12(6):. PubMed ID: 32545832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-vivo comparison of the neurotoxic potencies of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA.
    Kutschenko A; Manig A; Reinert MC; Mönnich A; Liebetanz D
    Neurosci Lett; 2016 Aug; 627():216-21. PubMed ID: 27268041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The rat Digit Abduction Score (DAS) assay: a physiological model for assessing botulinum neurotoxin-induced skeletal muscle paralysis.
    Broide RS; Rubino J; Nicholson GS; Ardila MC; Brown MS; Aoki KR; Francis J
    Toxicon; 2013 Sep; 71():18-24. PubMed ID: 23707612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AbobotulinumtoxinA (Dysport
    Field M; Splevins A; Picaut P; van der Schans M; Langenberg J; Noort D; Snyder D; Foster K
    Toxins (Basel); 2018 Dec; 10(12):. PubMed ID: 30551641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Pharmacodynamics of Three Different Botulinum Toxin Type A Preparations following Repeated Intramuscular Administration in Mice.
    Byun J; Kwak S; Kwon JH; Shin M; Lee DK; Rhee CH; Kang WH; Oh JW; Cruz DJM
    Toxins (Basel); 2022 May; 14(6):. PubMed ID: 35737026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteins.
    Jimenez-Shahed J
    Neuropsychiatr Dis Treat; 2012; 8():13-25. PubMed ID: 22275842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measuring the potency labelling of onabotulinumtoxinA (Botox(®)) and incobotulinumtoxinA (Xeomin (®)) in an LD50 assay.
    Dressler D; Mander G; Fink K
    J Neural Transm (Vienna); 2012 Jan; 119(1):13-5. PubMed ID: 21971766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pharmacodynamic comparison study of different botulinum toxin type A preparations.
    Kim SB; Ban B; Jung KS; Yang GH
    Dermatol Surg; 2013 Jan; 39(1 Pt 2):150-4. PubMed ID: 23301818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing incobotulinumtoxinA (Xeomin®) and onabotulinumtoxinA (Botox®): identical potency labelling in the hemidiaphragm assay.
    Dressler D; Pan L; Bigalke H
    J Neural Transm (Vienna); 2018 Sep; 125(9):1351-1354. PubMed ID: 29946929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative potency of incobotulinumtoxinA vs onabotulinumtoxinA a meta-analysis of key evidence.
    Jandhyala R
    J Drugs Dermatol; 2012 Jun; 11(6):731-6. PubMed ID: 22648220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Quantitative Analysis of OnabotulinumtoxinA, AbobotulinumtoxinA, and IncobotulinumtoxinA: A Randomized, Double-Blind, Prospective Clinical Trial of Comparative Dynamic Strain Reduction.
    Wilson AJ; Chang B; Taglienti AJ; Chin BC; Chang CS; Folsom N; Percec I
    Plast Reconstr Surg; 2016 May; 137(5):1424-1433. PubMed ID: 27119918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing lanbotulinumtoxinA (Hengli
    Pan L; Bigalke H; Kopp B; Jin L; Dressler D
    J Neural Transm (Vienna); 2019 Dec; 126(12):1625-1629. PubMed ID: 31707463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potency evaluation of a formulated drug product containing 150-kd botulinum neurotoxin type A.
    Hunt T; Clarke K
    Clin Neuropharmacol; 2009; 32(1):28-31. PubMed ID: 18978494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Botulinum toxin therapy of cervical dystonia: comparing onabotulinumtoxinA (Botox(®)) and incobotulinumtoxinA (Xeomin (®)).
    Dressler D; Tacik P; Adib Saberi F
    J Neural Transm (Vienna); 2014 Jan; 121(1):29-31. PubMed ID: 23913131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Pharmacodynamics Study of 3 Different Botulinum Toxin Type A Preparations in Mice.
    Kwak S; Kang WH; Rhee CH; Yang GH; Cruz DJM
    Dermatol Surg; 2020 Dec; 46(12):e132-e138. PubMed ID: 32251006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abo-, inco-, ona-, and rima-botulinum toxins in clinical therapy: a primer.
    Chen JJ; Dashtipour K
    Pharmacotherapy; 2013 Mar; 33(3):304-18. PubMed ID: 23400888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two different types of botulinum toxins: Is there a difference in efficacy and longevity?
    Shome D; Kapoor R; Khare S
    J Cosmet Dermatol; 2019 Dec; 18(6):1635-1641. PubMed ID: 31135088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of preferences between onabotulinumtoxinA (Botox) and incobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm.
    Chundury RV; Couch SM; Holds JB
    Ophthalmic Plast Reconstr Surg; 2013; 29(3):205-7. PubMed ID: 23552607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Validation of the Equivalence of the Cell-Based Potency Assay Method with a Mouse LD
    Yang Y; Zhang H; Yuan L; Wang S; Ma X
    Toxins (Basel); 2024 Jun; 16(6):. PubMed ID: 38922173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.